RIGEL PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
RIGL$43.91+4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity (Deficit)
(In thousands, except number of shares)
| Common Stock · AdditionalPaid-inCapital · Accumulated OtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity (Deficit) | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of January 1, 2023 | 17,339,816 | $17 | $1,368,979 | $(153) | $(1,382,459) | $(13,616) |
| Net loss | — | — | — | — | (25,091) | (25,091) |
| Net change in unrealized gain on short-term investments | — | — | — | 161 | — | 161 |
| Issuance of common stock upon exercise of options and participation in Purchase Plan | 99,196 | — | 1,049 | — | — | 1,049 |
| Issuance of common stock upon vesting of restricted stock units (RSUs) | 43,501 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 8,853 | — | — | 8,853 |
| Balance as of December 31, 2023 | 17,482,513 | 17 | 1,378,881 | 8 | (1,407,550) | (28,644) |
| Net loss | — | — | — | — | 17,485 | 17,485 |
| Net change in unrealized gain on short-term investments | — | — | — | 2 | — | 2 |
| Issuance of common stock upon exercise of options and participation in Purchase Plan | 158,795 | 1 | 1,963 | — | — | 1,964 |
| Issuance of common stock upon vesting of RSUs | 68,908 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 12,481 | — | — | 12,481 |
| Balance as of December 31, 2024 | 17,710,216 | 18 | 1,393,325 | 10 | (1,390,065) | 3,288 |
| Net income | — | — | — | — | 367,024 | 367,024 |
| Net change in unrealized gain on short-term investments | — | — | — | 171 | — | 171 |
| Issuance of common stock upon exercise of options, net of shares withheld, and participation in Purchase Plan | 457,027 | — | 8,101 | — | — | 8,101 |
| Issuance of common stock upon vesting of RSUs | 143,691 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 12,896 | — | — | 12,896 |
| Balance as of December 31, 2025 | 18,310,934 | $18 | $1,414,322 | $181 | $(1,023,041) | $391,480 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.